Author name: David Lambert

Dr Lambert is a principal, managing partner and chief informatics officer of CE Dojo, and former affiliate consultant to Old Well Consulting responsible for their eLearning platform. Dr Lambert is a Diplomate of the American Board of Oral & Maxillofacial Surgery and former clinical pharmacist. Dr Lambert is former Assistant Professor of Oral & Maxillofacial Surgery at the Oregon Health & Sciences University in Portland, Oregon where he also studied Clinical Informatics within the Department of Medical Informatics and Clinical Epidemiology. Dr Lambert has lectured extensively on topics of surgery, pharmacology, the opiate crisis and is published within several peer-reviewed journals.

DEA Issues Guidance on Opioid Treatment Training for Medical Practitioners

The US Drug Enforcement Administration (DEA) has outlined an eight-hour training requirement on the treatment and management of opioid patients. The Medication Access and Training Expansion Act mandates the training for all DEA-registered providers, with the deadline for completion set for the date of a practitioner’s next scheduled DEA registration submission beginning on June 27. Graduates from medical and dental schools are exempt from the requirement. The training does not have to occur in one session, and courses previously undertaken in accordance with state-mandated continuing education will apply.

DEA Issues Guidance on Opioid Treatment Training for Medical Practitioners Read More »

FDA Approves OTC Naloxone

This article discusses the recent approval of the first over-the-counter naloxone nasal spray for use in reversing opioid overdoses. The U.S. Food and Drug Administration (FDA) has approved the first over-the-counter (OTC) naloxone nasal spray, Narcan, to help prevent opioid overdoses. The nasal spray is intended for use in adults and adolescents, and the FDA

FDA Approves OTC Naloxone Read More »

FDA Modernization Act 2.0

Congress has passed the FDA Modernization Act 2.0 as part of the recent omnibus bill, removing the requirement to use animal testing in drug development. This allows drug companies to use alternative safety-testing models, such as cell-based assays, organ chips and microphysiological systems, and sophisticated computer modeling. Proponents state these alternatives are cost-effective and provide

FDA Modernization Act 2.0 Read More »

The Fourth Wave Of The Opiate Crisis

For over two decades, the opioid crisis in the United States has been an urgent health care emergency. Initially driven by over-prescription of pharmaceutical opioids, this has evolved into a “fourth wave” marked by poly-substance use, combining opioids and methamphetamine, resulting in record-high deaths year after year. The Covid-19 pandemic has made the situation even

The Fourth Wave Of The Opiate Crisis Read More »

Shopping Cart
Scroll to Top
0